Kadcyla (ado-trastuzumab emtansine) - 160 mg Vial For Injection
Kadcyla (ado-trastuzumab emtansine) - 160 mg Vial For Injection
Previous
Next
Usage conditions apply
- Description (Brief)
- (From insert) KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either:
- --Received prior therapy for metastatic disease, or
- -- Developed disease rescurrence during or within six months of completing adjuvant therapy.
- Location
- Currently not on view
- Object Name
- pharmaceutical
- biological
- date made
- ca 2013
- product expiration date
- 2015-11
- maker
- Genentech, Inc.
- place made
- United States: California, South San Francisco
- Physical Description
- plastic (overall material)
- glass (overall material)
- metal (overall material)
- cardboard (overall material)
- ado-trastuzumab emtansine, 160mg (overall ingredient)
- Measurements
- overall: 1 1/2 in x 2 3/4 in x 5 1/4 in; 3.81 cm x 6.985 cm x 13.335 cm
- bottle of kadcyla: 2 1/2 in x 1 1/4 in; 6.35 cm x 3.175 cm
- overall: 5 3/8 in x 2 3/4 in x 1 3/8 in; 13.6525 cm x 6.985 cm x 3.4925 cm
- ID Number
- 2013.0069.06
- catalog number
- 2013.0069.06
- accession number
- 2013.0069
- Credit Line
- Gift of Genentech, Inc.
- subject
- Women's Health
- See more items in
- Medicine and Science: Medicine
- Health & Medicine
- The Antibody Initiative
- Antibody Initiative: Monoclonal Antibodies
- Data Source
- National Museum of American History
Nominate this object for photography.
Our collection database is a work in progress. We may update this record based on further research and review. Learn more about our approach to sharing our collection online.
If you would like to know how you can use content on this page, see the Smithsonian's Terms of Use. If you need to request an image for publication or other use, please visit Rights and Reproductions.
Note: Comment submission is temporarily unavailable while we make improvements to the site. We apologize for the interruption. If you have a question relating to the museum's collections, please first check our Collections FAQ. If you require a personal response, please use our Contact page.
